OVIDE (malathion) lotion 0.5% updated its manufacturing process for the active pharmaceutical ingredient. As such, Taro Pharmaceuticals changed the NDC number to 51672-5276-4 to reflect this. Product with old NDC number may be used until the expiration date printed on the box.

Comparative In Vitro Pediculicidal Efficacy of Treatments in a Resistant Head Lice Population in the United States. The correlation between in vitro studies and clinical outcome has not been established.

View the study

OVIDE® and TaroPharma® are trademarks of Taro Pharmaceuticals U.S.A., Inc. and/or its affiliates.

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Oct. 26, 2005--Taro Pharmaceutical Industries Ltd. ("Taro," Nasdaq: TARO) reported today that its U.S. affiliate will initiate a multi-center Phase III study in the United States to evaluate a novel formulation of Ovide®, a prescription product for control of head lice (Pediculus humanus capitis) in pediatric and adult subjects.Click for full story

HAWTHORNE, NY - June 12, 2006 (INB) -- TaroPharma, a division of Taro Pharmaceuticals U.S.A., Inc., is pleased to announce that a rebate up to $50 for OVIDE® (malathion) Lotion, 0.5% is available on the www.ovide4headlice.com website. Finding out your child or other family member has head lice is unpleasant news. Head lice season is just around the corner, and the people that stand behind the clinically proven head lice treatment product, OVIDE®, are pleased to offer this rebate to assist you during your treatment process. Click for full story